Here is the design of a clinical trial:

Official Title: A Randomized, Open-labelled, Controlled Trial Evaluating the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.

Included conditions:
- Breast Cancer

Study Armgroups:
- {'label': 'Experimental arm', 'type': 'EXPERIMENTAL', 'description': 'For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga (the first on site and by videoconference for the others).\n\nStarting the first day of the yoga practice there will be one daily 15 min session at home with "My Yoga Guide" and the audio guide during 12 weeks.', 'interventionNames': ['Behavioral: educational yoga program']}
- {'label': 'control arm', 'type': 'PLACEBO_COMPARATOR', 'description': 'The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.', 'interventionNames': ['Other: no intervention']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'educational yoga program', 'description': 'Daily 15-min yoga sessions at home with the "Le guide du yoga" and the audio-guide, during 12 weeks.\n\nOne 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)', 'armGroupLabels': ['Experimental arm']}
- {'type': 'OTHER', 'name': 'no intervention', 'description': 'no yoga session at home and no yoga -therapeutic educatuion session', 'armGroupLabels': ['control arm']}

Primary Outcomes:
- {'measure': 'the efficacy of a combined intervention of physical therapy and yoga, including patient education with a control group for confirmed osteoarticular and/or musculoskeletal pain (≥4) due to hormone therapy in patients treated for breast cancer.', 'description': 'Rate of patients with a 2-point reduction on the Numeric Pain Rating Scale (NPRS) of osteoarticular and/or musculoskeletal pain due to hormonal therapy treatment between T0 (inclusion) and T2 (end of treatment).', 'timeFrame': '12 weeks'}

Please estimate the sample size based on the assumption: 
The sample size calculation is based on a bilateral alpha risk of 5%, a power of 80%, and an allowance for 10% potentially non-evaluable patients.
Sample size
        The sample size calculation is based on the comparison of the proportion of patients who will report a reduction of at least two units of their osteoarticular and/or musculoskeletal pain due to HT between T0 and T2 in each group, assessed on the NPRS from 0 to 10. Indeed, a reduction of two units measured on the NPRS is considered as the minimal clinically important difference in chronic musculoskeletal pain intensity.38 To detect a difference of 25% between the control and the experimental groups (15% vs 40%) and based on a bilateral alpha risk of 5%, with a power of 80%, 98 patients, 49 per group, would be required. Accounting for 10% of potentially non-evaluable patients, 108 patients are to be included in the study, with 54 patients per group.